6 results about "Peste-des-Petits-Ruminants" patented technology

The invention relates to a primer-probe set, comprising a forward primer having the nucleotide sequence of SEQ ID NO:1 and a reverse primer having the nucleotide sequence of SEQ ID NO:2, and a peptide nucleic acid (PNA) probe having the sequence of HEX-OO-(SEQ ID NO:3)-Lysine-BHQ1, which are used for differentiating the Peste des Petits Ruminants (PPR) virus vaccine and field strains and for preventing false positive results arising from the PPR vaccine, as well as to their operating temperatures. Said primer-probe set can differentiate between the vaccine strain containing the nucleotide sequence of SEQ ID NO:4 and the field strain containing the nucleotide sequence of SEQ ID NO:5. Thus, by means of said primer-probe set, false positive results arising from the PPR vaccine are prevented, and accordingly, unnecessary quarantine measures are also avoided.

The invention discloses an application of an intestinal strain in preparation of a cholesterol-lowering product, and belongs to the technical field of microbial medicines. The intestinal bacterial strain is Oscillibacter ruminant, the viable bacteria concentration of the intestinal bacterial strain is controlled to be (4.8-5.2) * 10 < 9 > CFU / mL, the intestinal bacterial strain can be prepared into bacterial liquid, freeze-dried powder, capsules or tablets and other dosage forms, and pharmaceutically acceptable auxiliary materials such as lactose and microcrystalline cellulose can be added. According to the cholesterol-lowering product, the total cholesterol, triglyceride and low-density lipoprotein cholesterol level of an object can be remarkably reduced under the action of peste des petits ruminants, and meanwhile, the high-density lipoprotein cholesterol level is increased; in addition, abnormal blood glucose induced by high-fat diet can be improved, arterial lipid accumulation is reduced, and the plaque area proportion of atherosclerotic lesions is improved.

The application discloses a kind of PPRV-F nanobody and nanobody preparation, purification and neutralization test method, and wherein, the PPRV-F nanobody includes the amino acid sequence shown in SEQ ID NO:1.The preparation and purification method of the nanobody provided in the application can obtain the PPRV-F nanobody with neutralization titer reaching 1:20.The nanobody prepared in the application can be used for the treatment, prevention of PPR and the detection of PPRV.

The application provides a use of remdesivir in preparation of a preparation for preventing and / or treating peste des petits ruminants virus, and belongs to the technical field of biological medicine. The application finds that the use of remdesivir in a safe concentration range can significantly inhibit the replication of the peste des petits ruminants virus in host cells, obviously reduce the expression level of virus-related genes and proteins, and exhibit good antiviral activity. Meanwhile, the inhibitory effect of remdesivir on the PPRV presents obvious dose dependence, and with the increase of the acting concentration, the antiviral effect is significantly enhanced, which indicates that the effect is stable and has strong controllability. Moreover, remdesivir mainly acts on the virus replication stage, can effectively block the virus replication process, thereby reducing the virus infection level and reducing the generation of daughter virus particles. The application provides a new technical approach for the prevention and treatment of peste des petits ruminants, makes up for the deficiency of lack of effective antiviral drugs in the prior art, and has a good application prospect.

The invention belongs to the technical field of biotechnology detection, and relates to a primer probe combination for identifying peste des petits ruminants vaccine strains and wild strains and a detection method of the peste des petits ruminants vaccine strains and the wild strains. The invention discloses a primer pair and a probe for identifying a peste des petits ruminants vaccine strain and a wild strain. The primer pair comprises an upstream primer and a downstream primer, wherein the upstream primer is PPRV-qF: TCGGAAGAACATACYGTC, and the downstream primer is PPRV-qR: CRACTCGAAGACTCTTTAA; the nucleotide sequence of the probe for detecting the peste des petits ruminants vaccine strain is FAM-ACCGAGCACCAGTCCAGGTAT-BHQ1, and the nucleotide sequence of the probe for detecting the peste des petits ruminants vaccine strain is The nucleotide sequence of the probe for detecting the peste des petits ruminants wild strain is HEX-ATCCGAGCACCGATCTAGGTATC-BHQ1, and the nucleotide sequence of the probe for detecting the peste des petits ruminants wild strain is HEX- The peste des petits ruminants vaccine strain and the wild strain can be identified and detected only by a pair of primers and two probes marked by different fluorophores.

This invention belongs to the field of goat vaccine technology and is an application of a vaccine for the prevention of small ruminant plague (PPR) and sheep pox. This PPR-sheep pox vaccine is an improvement on the injection method of a bivalent live PPR-sheep pox vaccine, suitable for doubling the intramuscular injection in goats. Each injection of 1 ml of the bivalent live PPR-sheep pox vaccine results in a population antibody titer of 70% for both PPR and sheep pox after 30 days, and sheep pox antibody titer can still be detected after 180 days. This PPR-sheep pox vaccine demonstrates good safety and PPR immunity protection in Alashan white cashmere goats. Furthermore, the vaccine is suitable for intramuscular injection, which meets the needs of sheep pox immunization and control, and is suitable for practical grassroots disease prevention operations. It provides important technical support for the scientific prevention and control of diseases in regional white cashmere goats. Promoting the use of this PPR-sheep pox vaccine can prevent both PPR and sheep pox.